Previous 10 | Next 10 |
ALACHUA and TAMPA, Fla., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, announced that it will participate in the 77 th Annual Meeting of the Amer...
AxoGen, Inc. (AXGN) Q2 2022 Results Conference Call August 3, 2022 4:30 PM ET Company Participants Ed Joyce - Director, IR Karen Zaderej - Chairman, President & CEO Peter Mariani - EVP & CFO Conference Call Participants Presentation ...
The following slide deck was published by AxoGen, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: AxoGen, Inc. 2022 Q2 - Results - Earnings Call Presentation
AxoGen press release ( NASDAQ: AXGN ): Q2 Non-GAAP EPS of -$0.06 (vs. -$0.09 Y/Y). Revenue of $34.5M (vs. $33.6M Y/Y). FY22 revenue outlook is in the range of $135.0M to $142.0M (vs. consensus of $138.38M). Shares +0.29% . For further details see: Axo...
ALACHUA, Fla. and TAMPA, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended June...
AxoGen is set to report Q2 FY22 earnings on Wednesday, following a period of flat performance on the chart. The company released top-line forecasts in its earnings pre-release from July, implying a period of growth. We demonstrate that investors look to have positioned on the long...
ALACHUA. Fla. and TAMPA, Fla, July 29, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO, and president, will present at Canaccord G...
Axogen ( NASDAQ: AXGN ) reported Monday preliminary estimates for its second quarter with revenue up 2% Y/Y to $34.4M vs. consensus of $33.29M The growth in revenue is expected to be 8% when excluding the impact of $1.8M revenue of Avive Soft Tissue Membrane in th...
Organizational updates are part of plan to bring additional focus on leveraging clinical data to accelerate market development and the pace of innovation Preliminary unaudited second quarter revenue of approximately $34.4 million Company will report full second quarter res...
ALACHUA, Fla. and TAMPA, Fla., July 11, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that, effective July 11, 2022, William Burke has been appointed to its Board...
News, Short Squeeze, Breakout and More Instantly...
ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, b...
2024-07-01 07:30:05 ET Raymond James analyst issues OUTPERFORM recommendation for AXGN on July 1, 2024 05:51AM ET. AXGN was trading at $7.24 at issue of the analyst recommendation. Historical Analyst Recommendations Latest 10 recommendations
ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an inducement grant on July 1, 2024, under NASDAQ listing rule 5635(c)(4) in conn...